NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
Clinical Trials
16 trialsNCT05494697 2025-10-14
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
AIM ImmunoTech Inc.
Phase 2 Suspended
NCT03417921 2025-10-01
Pancreatic
Ability Pharmaceuticals SL
Phase 1/2 Suspended
NCT04693546 2025-09-26
PREVENT
Metabiomics Corp
Suspended
NCT05958199 2025-06-27
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
Phase 1 Suspended
NCT05603572 2025-06-05
KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
Primocure Pharma
Phase 1/2 Suspended
NCT05191667 2025-02-13
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Suspended
NCT04714983 2024-04-09
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Phase 1 Suspended
NCT04650451 2023-04-20
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Bellicum Pharmaceuticals
Phase 1 Suspended
NCT03253575 2019-04-08
ANCERS-2
Mitra RxDx, Inc.
Suspended
NCT02026362 2017-10-18
HCC DC CTL
HRYZ Biotech Co.
Phase 1/2 Suspended
NCT00909558 2010-02-24
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
Envita Medical Center, Inc.
Phase 1 Suspended
NCT00637364 2009-01-13
HIFU Pancreas
CMED HIFU Development Corporation
Phase 1/2 Suspended
NCT00443573 2008-05-07
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
ARCA Biopharma, Inc.
Phase 1/2 Suspended
NCT00536770 2007-11-06
A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
Novacea
Phase 2 Suspended
NCT00048529 2005-06-24
Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus
Tularik
Phase 2 Suspended